Rosuvastatin induced carotid plaque regression in patients with inflammatory joint diseases: The RORA-AS study.

S Rollefstad, E Ikdahl, J Hisdal, I C Olsen, I Holme, H B Hammer, K T Smerud, G D Kitas, T R Pedersen, T K Kvien, A G Semb

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Objective Patients with rheumatoid arthritis (RA) and carotid artery plaques (CP) have increased risk of acute coronary syndromes. Statin treatment with low density lipoprotein cholesterol (LDL-c) goal ≤ 1.8 mmol/L (≤70mg/dl) is recommended for patients with CP in the general population. In the ROsuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and other inflammatory joint diseases (RORA-AS) study, the aim was to evaluate the effect of 18 months intensive lipid lowering with rosuvastatin with regard to change in CP height. Methods Eighty-six patients (60.5% female) with CP and IJD [RA (n=55), ankylosing spondylitis (n=21) and psoriatic arthritis (n=10)] were treated with rosuvastatin to obtain LDL-c goal. CP height was evaluated by B-mode ultrasound. Results The mean±SD age was 60.8±8.5 years, and the median compliance of rosuvastatin use was 97.9% (IQR 96.0, 99.4). At baseline, the median number and height of the CP was 1.0 (range 1-8) and 1.80mm (IQR 1.60, 2.10), respectively. Change in CP height after 18 months rosuvastatin treatment was -0.19±0.35mm (p
    Original languageEnglish
    JournalArthritis & rheumatology (Hoboken, N.J.)
    DOIs
    Publication statusPublished - 16 Mar 2015

    Fingerprint

    Dive into the research topics of 'Rosuvastatin induced carotid plaque regression in patients with inflammatory joint diseases: The RORA-AS study.'. Together they form a unique fingerprint.

    Cite this